As shown in prior studies, inhibiting glycolysis or glutamine using specific inhibitors could radiosensitize certain NSCLC cell lines, with efficacy closely tied to molecular features such as KRAS mutation status [47]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.